A Comparison of Efficacy and Safety of Two Lipid-Based Lubricant Eye Drops for the Management of Evaporative Dry Eye Disease

被引:14
|
作者
Jerkins, Gary [1 ]
Greiner, Jack, V [2 ,3 ]
Tong, Louis [4 ,5 ,6 ]
Tan, Jacqueline [7 ]
Tauber, Joseph [8 ]
Mearza, Ali [9 ,10 ]
Srinivasan, Sruthi [11 ]
机构
[1] Adv Vis Res LLC, Nashville, TN 37205 USA
[2] Clin & & Res Boston, Boston, MA USA
[3] Harvard Med Sch, Dept Ophthalmol, Boston, MA 02115 USA
[4] Natl Univ Singapore, Singapore Natl Eye Ctr, Singapore, Singapore
[5] Singapore Eye Res Inst, Singapore, Singapore
[6] Duke Natl Univ, Singapore Med Sch, Singapore, Singapore
[7] Univ New South Wales, Sydney, NSW, Australia
[8] Tauber Eye Ctr, Kansas City, MO USA
[9] Imperial Coll Healthcare NHS Trust, London, England
[10] Ophthalm Consultants London, London, England
[11] Alcon Res LLC, Johns Creek, GA USA
来源
CLINICAL OPHTHALMOLOGY | 2020年 / 14卷
关键词
dry eye; lipid-deficient; evaporative dry eye; lubricant eye drops; non-inferiority; ARTIFICIAL TEARS; MULTICENTER; DEFICIENT; EMULSION; LAYER;
D O I
10.2147/OPTH.S256351
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: The aim of this study was to compare the efficacy of two lipid-based lubricant eye drops in patients with lipid-deficient dry eye. Methods: This Phase IV, multicenter, prospective, double-masked study enrolled adults (aged >= 18 years) who had a tear film breakup time (TFBUT) of <= 15 seconds(s), and unanesthetized Schirmer I test of >= 3 mm to <= 12 mm in at least one eye, at both screening and baseline visits. Eligible patients (n=231) were randomized (1:1) and received either Systane (R) Balance (SYSB; n=117) or Refresh (R) Optive Advanced (RFO-Ad, n=114), four-times a day, for 35 days. The primary endpoint was non-inferiority for change from baseline in TFBUT at Day 35 (noninferiority was established if the lower limit of the 95% confidence interval (CI) for the difference between the treatment groups was > -1.0 s); secondary endpoints (test of superiority) were change in TFBUTand global ocular discomfort visual analog scale (VAS) score at Day 35. Other endpoints included the impact of dry eye on everyday life (IDEEL) treatment satisfaction scores (inconvenience and effectiveness) and safety. Results: At Day 35, themean change from baseline in TFBUTwas 0.998 s in the SYSB and 0.868 s in the RFO-Ad groups with a treatment difference: 0.130 s; (95% CI -0.34, 0.60; P<0.0001) demonstrating non-inferiority of SYSB to RFO-Ad. The global ocular discomfort VAS scores improved in both groups, with a mean change from baseline of -9.7 and -8.8 in SYSB and RFOAd groups (treatment difference -0.8; P=0.62), respectively. No meaningful difference was observed in IDEEL treatment effectiveness and treatment inconvenience scores between SYSB vs RFO-Ad (P>0.05 for treatment difference). Both treatments were well tolerated. Conclusion: SYSB lubricant eye drops were non-inferior to RFO-Ad for improvement in TFBUT in patients with lipid-deficient dry eye. Both lubricant eye drops improved TFBUT and ocular discomfort scores in patients with lipid-deficient dry eye.
引用
收藏
页码:1665 / 1673
页数:9
相关论文
共 50 条
  • [31] Short-Term Efficacy and Safety of Scleral Lenses in the Management of Severe Dry Eye in a Chinese Population
    Lu, Chuwei
    Han, Danjie
    Zeng, Li
    Hong, Jiaxu
    Fadel, Daddi
    Zhou, Xingtao
    Chen, Zhi
    Le, Qihua
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (03)
  • [32] The efficacy and safety of qiming granule in dry eye disease Protocol for systematic review and meta-analysis
    Yang, Maoyi
    Hu, Zhipeng
    Yue, Rensong
    Yang, Liangjun
    Zhang, Boxun
    Chen, Yuan
    MEDICINE, 2019, 98 (39)
  • [33] Managing Dry Eye Disease with Novel Medications: Mechanism, Study Validity, Safety, Efficacy, and Practical Application
    Wong, Jason C.
    Barak, Aselle
    PHARMACY, 2024, 12 (01)
  • [34] Viscous carbomer eye drops in patients with dry eyes - Efficacy and safety. A randomized, open, cross-over, multicentre study
    Marner, K
    Moller, PM
    Dillon, M
    RaskPedersen, E
    ACTA OPHTHALMOLOGICA SCANDINAVICA, 1996, 74 (03): : 249 - 252
  • [35] Efficacy and safety of dual-polymer hydroxypropyl guar- and hyaluronic acid-containing lubricant eyedrops for the management of dry-eye disease: a randomized double-masked clinical study
    Labetoulle, Marc
    Schmickler, Stefanie
    Galarreta, David
    Boehringer, Daniel
    Ogundeles, Abayomi
    Guillon, Michel
    Baudouin, Christophe
    CLINICAL OPHTHALMOLOGY, 2018, 12 : 2499 - 2508
  • [36] The efficacy and safety of varenicline nasal spray for the management of dry eye signs: a systematic review and meta-analysis
    Bashrahil, Bader
    Taher, Nada
    Alzahrani, Ziyad
    Alnabihi, Ahmed
    Aldahlawi, Abdulaziz
    Alkhathlan, Mohammed
    Alghamdi, Saeed
    BMC OPHTHALMOLOGY, 2023, 23 (01)
  • [37] Safety and efficacy of autologous serum eye drop for treatment of dry eyes in graft-versus-host disease
    Azari, Amir A.
    Karadag, Remzi
    Kanavi, Mozhgan Rezaei
    Nehls, Sarah
    Barney, Neal
    Kim, Kyungmann
    Longo, Walter
    Hematti, Peiman
    Juckett, Mark
    CUTANEOUS AND OCULAR TOXICOLOGY, 2017, 36 (02) : 152 - 156
  • [38] Efficacy and safety of the disposable eyelid warming masks in the treatment of dry eye disease due to Meibomian gland dysfunction
    Wang, Da-Hu
    Guo, Hua
    Xu, Wei
    Liu, Xin-Quan
    BMC OPHTHALMOLOGY, 2024, 24 (01)
  • [39] Safety and Efficacy of Cyclosporine (0.05% versus 0.09%) in Dry Eye Disease. Is it the Strength of Cyclosporin that Really Matters?
    Rajpoot, Mukesh
    Singh, Divya
    Pandey, Kankambari
    Bhargava, Rahul
    NEPALESE JOURNAL OF OPHTHALMOLOGY, 2022, 14 (02) : 64 - 77
  • [40] The Comparison between the Composition of 100% Autologous Serum and 100% Platelet-Rich Plasma Eye Drops and Their Impact on the Treatment Effectiveness of Dry Eye Disease in Primary Sjogren Syndrome
    Wrobel-Dudzinska, Dominika
    Przekora, Agata
    Kazimierczak, Paulina
    Cwiklinska-Haszcz, Agnieszka
    Kosior-Jarecka, Ewa
    Zarnowski, Tomasz
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (09)